6 research outputs found
Recent Advances in Diffuse Large B Cell Lymphoma
More recently, DLBCL has witnessed advances in the molecular profiling and treatment of patients with refractory and relapsed disease. DLBCL is biologically and clinically a heterogeneous disease. Despite its aggressive behavior, DLBCL is a potentially curable disease with overall survival of 94 and 55% in patients with low and high rIPI scores, respectively. The combination of anti-CD 20 monoclonal antibody rituximab and cyclophosphamide, doxorubicin, oncovin (vincristine) and prednisone (R-CHOP) chemotherapy every 3 weeks is the first line treatment. Radiotherapy is reserved for the patients with bulky disease who fail to achieve complete remission after first line treatment. CNS prophylaxis is reserved for the patients with high lactate dehydrogenase (LDH) levels and involvement of more than one extranodal sites and for the patients with involvement of selective extranodal sites like testes and orbits (the sanctuary sites). Patients who suffer relapse after first line treatment receive high-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT). Variants of DLBCL like double-hit (presence of MYC and BCL2/BCL6) and triple-hit (presence of MYC, BCL2 and BCL6) lymphomas are treated differently and these patients have worse outcome. Several novel immunotherapeutic agents like checkpoint inhibitors and chimeric antigen receptor T cell (CART) are being investigated in randomized trials on patients with DLBCL
Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: A prospective study
Background: Long-term therapy with antiepileptic drugs (AED) may be
associated with increased total serum alkaline phosphatase (ALP) levels
and reduced serum calcium, inorganic phosphorous, and vitamin D levels.
These adverse biochemical alterations have an adverse effect on bone
health Objective: To determine (a) onset of derangements in serum
total ALP and its isoenzymes (liver, bone), calcium and 25-hydroxy
vitamin D (25-OHD) concentrations after initiation of treatment with
phenytoin or valproic acid monotherapy and (b) the effect of
simultaneous supplementation with calcium and 25-OHD at recommended
daily allowance (RDA) dosage, on these biochemical parameters.
Materials and Methods: Study was a prospective, case-controlled study
in adults. Serum biochemical parameters were estimated at baseline, 30,
60, and 90 days of starting AED treatment in the study subjects:
Groups--A (only calcium supplementation) and Group B (both calcium and
25-OHD supplementation). Statistical Analysis: Mean±SD, and
students′ paired t test (between groups A and B) unpaired
students′ t test (drug-wise). Results: At 60 days of AED therapy
Group A showed a significant increase in serum total ALP
(78.83±11.04 to101.75 ± 9.56 IU/l) (P < 0.001), ALP-liver
isoenzyme, (41.97± 10.81 to 68.83 ±7.81 IU/L) (P < 0.001),
significant decrease in calcium (9.30 ± 0.36 to 8.80 ± 0.38
mg%) (P < 0.001), ALP-bone isoenyzme (36.84 ± 5.01 to 32.92
± 6.46 IU/L) (P < 0.001), and a significant decrease in 25-OHD
(25.19 ± 5.98 to 19.76 ± 5.35 ng/ml) (P < 0.001) at 90
days. In contrast Group B, at 60 days, showed a significant decrease in
serum total ALP (81.92 ± 19.63 to 54.77. ± 11.53 IU/L) (P
< 0.0001), ALP-liver isoenzyme (48.01. ± 13.53 to 28.12. ±
5.88 IU/L) (P < 0.0001), significant increase in calcium ((9.24
± 0.31 to 9.93 ± 0.26 mg%) (P < 0.001) and ALP-bone
isoenzyme levels (33.93 ± 12.2 to 26.25 ± 8.23 IU/L). In
Group B, 25-OHD levels showed a significant increase at 90 days (24.36
± 3.42 to 31.53 ± 327 ng/ml) (P < 0.0001). Conclusion:
Biochemical derangements in calcium metabolism involving the bone are
seen by 60 days after starting AED monotherapy, indicating
predisposition to development of osteomalacia in these patients. This
is preventable by simultaneous oral supplementation with calcium and
25-OHD